MHLW approves Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer October 3, 2023
Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial September 26, 2023
European Commission Approves ORSERDU in Patients with ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer September 26, 2023
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial August 16, 2023
Ph 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer August 2, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
Positive CHMP Opinion to ORSERDU® (Elacestrant) for ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer patients July 22, 2023
Eisai Transfers All Future Economic Rights for Elacestrant, a Selective Estrogen Receptor Degrader, to DRI Healthcare July 19, 2023
Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer July 19, 2023
Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer June 21, 2023
CytoMed Therapeutics Announces Research Collaboration with Cancer Treatment Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology May 18, 2023
New Results from Ph 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an ADC May 18, 2023
First Patient Dosed in Ph 1/2 Trial of STX-478 for the Treatment of Breast Cancer and Other Solid Tumors May 10, 2023
Ph 2/3 Trial for Eftilagimod Alpha plus Paclitaxel initiated in Metastatic Breast Cancer March 31, 2023
Kisqali® Ph 3 NATALEE Trial Meets Primary Endpoint At Interim Analysis Demonstrating Clinically Meaningful Benefit In Patients With Early Breast Cancer March 31, 2023
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials March 31, 2023
